Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Colleen A. Lawton MD

Colleen A. Lawton MD

Vice Chair, Professor

Institution: Medical College of Wisconsin
Department: Radiation Oncology
Program: Clinical

Member of the Cancer Center


Publications

  • Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202. (Lawton CAF, Lin X, Hanks GE, Lepor H, Grignon DJ, Brereton HD, Bedi M, Rosenthal SA, Zeitzer KL, Venkatesan VM, Horwitz EM, Pisansky TM, Kim H, Parliament MB, Rabinovitch R, Roach M 3rd, Kwok Y, Dignam JJ, Sandler HM) Int J Radiat Oncol Biol Phys 2017 Jun 01;98(2):296-303 PMID: 28463149 PMCID: PMC5603177 05/04/2017
  • Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621. (Hurwitz MD, Harris J, Sartor O, Xiao Y, Shayegan B, Sperduto PW, Badiozamani KR, Lawton CAF, Horwitz EM, Michalski JM, Roof K, Beyer DC, Zhang Q, Sandler HM) Cancer 2017 Jul 01;123(13):2489-2496 PMID: 28323339 PMCID: PMC5474197 03/23/2017
  • Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. (Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, NRG Oncology RTOG) N Engl J Med 2017 02 02;376(5):417-428 PMID: 28146658 PMCID: PMC5444881 02/02/2017
  • Biomarkers of Outcome in Patients With Localized Prostate Cancer Treated With Radiotherapy. (Hall WA, Lawton CA, Jani AB, Pollack A, Feng FY) Semin Radiat Oncol 2017 Jan;27(1):11-20 PMID: 27986207 12/18/2016
  • A Hybrid Adaptive Replanning Approach for Prostate Stereotactic Body Radiation Therapy. (Ates O, Ahunbay EE, Lawton CA, Li A) Int J Radiat Oncol Biol Phys 2016 Oct 1;96(2S):E668-E669 PMID: 27675309 09/28/2016
  • Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer. (Brower JV, Forman JD, Kupelian PA, Petereit DG, Gondi V, Lawton CA, Anger N, Saha S, Chappell R, Ritter MA) Radiother Oncol 2016 Jan;118(1):99-104 PMID: 26755165 PMCID: PMC4764419 01/13/2016
  • Watchful Waiting-Active Surveillance in Low-Risk Prostate Cancer. (Haffty BG, Lawton CA, Sandler H) JAMA Oncol 2015 Aug;1(5):688-9 PMID: 26182350 07/17/2015
  • Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413. (Hamstra DA, Bae K, Hanks G, Hu C, Shipley WU, Pan CC, Roach M 3rd, Lawton CA, Sandler HM) Cancer 2015 Mar 15;121(6):844-52 PMID: 25410885 PMCID: PMC4657945 11/21/2014
  • Assessment and management of interfractional variations in daily diagnostic-quality-CT guided prostate-bed irradiation after prostatectomy. (Liu F, Ahunbay E, Lawton C, Li XA) Med Phys 2014 Mar;41(3):031710 PMID: 24593714 03/07/2014
  • RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients. (Kachnic LA, Pugh SL, Tai P, Smith M, Gore E, Shah AB, Martin AG, Kim HE, Nabid A, Lawton CA) Prostate Cancer Prostatic Dis 2013 Dec;16(4):382-6 PMID: 24080992 PMCID: PMC3830691 10/02/2013
  • Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. (Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE) J Oncol Pract 2013 May;9(3):e90-5 PMID: 23942508 PMCID: PMC3651578 08/15/2013
  • Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413. (Cury FL, Hunt D, Roach M 3rd, Shipley W, Gore E, Hsu IC, Krisch RE, Seider MJ, Sandler H, Lawton C) Cancer 2013 Jun 01;119(11):1999-2004 PMID: 23504930 PMCID: PMC3663874 03/19/2013
  • National Radiation Oncology Registry: The pilot prostate cancer registry. (Nassif D, Chen RC, Hoffman KE, Kuban DA, Lawton CA, Michalski JM, Potters L, Rose CM, Sandler HM, Suh W, Wall T, Zietman AL, Bekelman JE) J Clin Oncol 2012 Dec;30(34_suppl):267 PMID: 28147066 12/01/2012
  • Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. (Gay HA, Barthold HJ, O'Meara E, Bosch WR, El Naqa I, Al-Lozi R, Rosenthal SA, Lawton C, Lee WR, Sandler H, Zietman A, Myerson R, Dawson LA, Willett C, Kachnic LA, Jhingran A, Portelance L, Ryu J, Small W Jr, Gaffney D, Viswanathan AN, Michalski JM) Int J Radiat Oncol Biol Phys 2012 Jul 01;83(3):e353-62 PMID: 22483697 PMCID: PMC3904368 04/10/2012
  • A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. (Jagsi R, Bekelman JE, Brawley OW, Deasy JO, Le QT, Michalski JM, Movsas B, Thomas CR Jr, Lawton CA, Lawrence TS, Hahn SM) Int J Radiat Oncol Biol Phys 2012 Oct 01;84(2):318-22 PMID: 22436790 03/23/2012
  • Impact of computed tomography image quality on image-guided radiation therapy based on soft tissue registration. (Morrow NV, Lawton CA, Qi XS, Li XA) Int J Radiat Oncol Biol Phys 2012 Apr 01;82(5):e733-8 PMID: 22349041 02/22/2012
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. (Lawton CA, Yan Y, Lee WR, Gillin M, Firat S, Baikadi M, Crook J, Kuettel M, Morton G, Sandler H) Int J Radiat Oncol Biol Phys 2012 Apr 01;82(5):e795-801 PMID: 22330999 02/15/2012
  • Radiation Therapy Oncology Group (RTOG) 9413: Randomized trial comparing whole pelvic radiotherapy (WPRT) to prostate only (PORT) and neoadjuvant hormone therapy (NHT) to adjuvant hormone therapy (AHT). (Roach M, Yan Y, Lawton CA, Hsu IJ, Lustig RA, Jones CU, Rotman M, Zeitzer KL, Werner-Wasik M, Kim H, Thomas CR, Shipley WU, Sandler HM) J Clin Oncol 2012 Feb 10;30(5_suppl):96 PMID: 28143343 02/10/2012
  • Developing a national radiation oncology registry: From acorns to oaks. (Palta JR, Efstathiou JA, Bekelman JE, Mutic S, Bogardus CR, McNutt TR, Gabriel PE, Lawton CA, Zietman AL, Rose CM) Pract Radiat Oncol 2012 Jan-Mar;2(1):10-7 PMID: 24674031 01/01/2012
  • Mitigation of late renal and pulmonary injury after hematopoietic stem cell transplantation. (Cohen EP, Bedi M, Irving AA, Jacobs E, Tomic R, Klein J, Lawton CA, Moulder JE) Int J Radiat Oncol Biol Phys 2012 May 01;83(1):292-6 PMID: 22104363 PMCID: PMC3299939 11/23/2011
  • Consolidating risk estimates for radiation-induced complications in individual patient: late rectal toxicity. (Prior P, Devisetty K, Tarima SS, Lawton CA, Semenenko VA) Int J Radiat Oncol Biol Phys 2012 May 01;83(1):53-63 PMID: 22024204 10/26/2011
  • Development of an online adaptive solution to account for inter- and intra-fractional variations. (Li XA, Liu F, Tai A, Ahunbay E, Chen G, Kelly T, Lawton C, Erickson B) Radiother Oncol 2011 Sep;100(3):370-4 PMID: 21924781 09/20/2011
  • Validation of an online replanning technique for prostate adaptive radiotherapy. (Peng C, Chen G, Ahunbay E, Wang D, Lawton C, Li XA) Phys Med Biol 2011 Jun 21;56(12):3659-68 PMID: 21610293 05/26/2011
  • Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). (Lawton CA, Hunt D, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky TM, Sandler H) Int J Radiat Oncol Biol Phys 2011 Sep 01;81(1):1-7 PMID: 21470793 PMCID: PMC3132830 04/08/2011
  • Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials. (Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H) Int J Radiat Oncol Biol Phys 2011 Dec 01;81(5):1293-301 PMID: 21458924 PMCID: PMC4675045 04/05/2011
  • Evaluation of nuclear factor κB and chemokine receptor CXCR4 co-expression in patients with prostate cancer in the Radiation Therapy Oncology Group (RTOG) 8610. (Okera M, Bae K, Bernstein E, Cheng L, Lawton C, Wolkov H, Pollack A, Dicker A, Sandler H, Sweeney CJ) BJU Int 2011 Jul;108(2 Pt 2):E51-8 PMID: 21156016 PMCID: PMC3062644 12/16/2010
  • Characterizing interfraction variations and their dosimetric effects in prostate cancer radiotherapy. (Peng C, Ahunbay E, Chen G, Anderson S, Lawton C, Li XA) Int J Radiat Oncol Biol Phys 2011 Mar 01;79(3):909-14 PMID: 20732764 08/25/2010
  • Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials. (Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H) Int J Radiat Oncol Biol Phys 2011 Jun 01;80(2):445-52 PMID: 20615632 PMCID: PMC2952349 07/10/2010
  • To treat pelvic nodes or not? Greater testicular scatter does not explain the results of randomized trials. (Roach M 3rd, Lawton CA, Chen J) J Clin Oncol 2010 Sep 01;28(25):e450-2 PMID: 20567007 06/23/2010
  • Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer. (Roach M 3rd, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H) Int J Radiat Oncol Biol Phys 2010 Dec 01;78(5):1314-22 PMID: 20378270 PMCID: PMC2920356 04/10/2010
  • Online adaptive replanning method for prostate radiotherapy. (Ahunbay EE, Peng C, Holmes S, Godley A, Lawton C, Li XA) Int J Radiat Oncol Biol Phys 2010 Aug 01;77(5):1561-72 PMID: 20362401 04/07/2010
  • Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. (Parker SM, Olteanu H, Vantuinen P, Lawton CA, Schultz CJ, Christians KK, Fenske TS) Int J Hematol 2009 Dec;90(5):616-22 PMID: 19937165 11/26/2009
  • Results of the Association of Directors of Radiation Oncology Programs (ADROP) survey of radiation oncology residency program directors. (Harris EE, Abdel-Wahab M, Spangler AE, Lawton CA, Amdur RJ) Int J Radiat Oncol Biol Phys 2009 Jun 01;74(2):327-37 PMID: 19427549 05/12/2009
  • Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. (Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Ménard C) Int J Radiat Oncol Biol Phys 2010 Feb 01;76(2):361-8 PMID: 19394158 PMCID: PMC2847420 04/28/2009
  • ACR appropriateness criteria on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology--prostate. (Michalski JM, Roach M 3rd, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR) Int J Radiat Oncol Biol Phys 2009 Jul 01;74(3):667-72 PMID: 19386445 04/24/2009
  • Hypofractionation for prostate cancer. (Ritter M, Forman J, Kupelian P, Lawton C, Petereit D) Cancer J 2009 Jan-Feb;15(1):1-6 PMID: 19197165 PMCID: PMC3039916 02/07/2009
  • A comparison of daily megavoltage CT and ultrasound image guided radiation therapy for prostate cancer. (Peng C, Kainz K, Lawton C, Li XA) Med Phys 2008 Dec;35(12):5619-28 PMID: 19175119 01/30/2009
  • RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. (Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M) Int J Radiat Oncol Biol Phys 2009 Jun 01;74(2):383-7 PMID: 18947938 PMCID: PMC2905150 10/25/2008
  • Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. (Lawton CA, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M 3rd, Pisansky TM, Seider M) Int J Radiat Oncol Biol Phys 2009 Jun 01;74(2):377-82 PMID: 18947941 PMCID: PMC2905162 10/25/2008
  • An on-line replanning scheme for interfractional variations. (Ahunbay EE, Peng C, Chen GP, Narayanan S, Yu C, Lawton C, Li XA) Med Phys 2008 Aug;35(8):3607-15 PMID: 18777921 09/10/2008
  • Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. (Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU) J Clin Oncol 2008 May 20;26(15):2497-504 PMID: 18413638 04/17/2008
  • Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413. (Taussky D, Bae K, Bahary JP, Roach M 3rd, Lawton CA, Shipley WU, Sandler HM) Urology 2008 Nov;72(5):1125-9 PMID: 18314175 03/04/2008
  • Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. (Roach M 3rd, Bae K, Speight J, Wolkov HB, Rubin P, Lee RJ, Lawton C, Valicenti R, Grignon D, Pilepich MV) J Clin Oncol 2008 Feb 01;26(4):585-91 PMID: 18172188 01/04/2008
  • Pelvic lymph node irradiation for prostate cancer: who, why, and when? (Wang D, Lawton C) Semin Radiat Oncol 2008 Jan;18(1):35-40 PMID: 18082586 12/18/2007
  • Designing equivalent treatment regimens for prostate radiotherapy based on equivalent uniform dose. (Li XA, Wang JZ, Stewart RD, Dibiase SJ, Wang D, Lawton CA) Br J Radiol 2008 Jan;81(961):59-68 PMID: 18039721 11/28/2007
  • Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. (Lawton CA, Bae K, Pilepich M, Hanks G, Shipley W) Int J Radiat Oncol Biol Phys 2008 Feb 01;70(2):437-41 PMID: 17881145 PMCID: PMC2917176 09/21/2007
  • Adjuvant androgen deprivation therapy augments cure and long-term cancer control in men with poor prognosis, nonmetastatic prostate cancer. (Fleshner N, Keane TE, Lawton CA, Mulders PF, Payne H, Taneja SS, Morris T) Prostate Cancer Prostatic Dis 2008;11(1):46-52 PMID: 17607304 07/04/2007
  • An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. (Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr) Int J Radiat Oncol Biol Phys 2007 Nov 01;69(3):646-55 PMID: 17531401 PMCID: PMC2917177 05/29/2007
  • A descriptive analysis of postimplant dosimetric parameters from Radiation Therapy Oncology Group P0019. (Lee WR, Bae K, Lawton CA, Gillin MT, Morton G, Firat S, Baikadi M, Kuettel M, Greven K, Sandler H) Brachytherapy 2006 Oct-Dec;5(4):239-43 PMID: 17118317 11/23/2006
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). (Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H) Int J Radiat Oncol Biol Phys 2007 Jan 01;67(1):39-47 PMID: 17084551 11/07/2006
  • Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. (Gillin MT, Dunning BF, Lawton CA, Foley WD, Byhardt RW, Morton G, Baikadi M, Pisansky TT, Michalski JM, Ibbott G, Lopez F, Radiation Therapy Oncology Group) Brachytherapy 2006 Jul-Sep;5(3):152-6 PMID: 16864066 07/26/2006
  • Early initiation of salvage hormone therapy influences survival in patients who failed initial radiation for locally advanced prostate cancer: A secondary analysis of RTOG protocol 86-10. (Shipley WU, Desilvio M, Pilepich MV, Roach M 3rd, Wolkov HB, Sause WT, Rubin P, Lawton CA) Int J Radiat Oncol Biol Phys 2006 Mar 15;64(4):1162-7 PMID: 16427211 01/24/2006
  • Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. (Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D) Int J Radiat Oncol Biol Phys 2005 Apr 01;61(5):1285-90 PMID: 15817329 04/09/2005
  • Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer. (Li XA, Wang JZ, Jursinic PA, Lawton CA, Wang D) Int J Radiat Oncol Biol Phys 2005 Mar 15;61(4):1251-7 PMID: 15752907 03/09/2005
  • Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. (Lawton CA, Winter K, Grignon D, Pilepich MV) J Clin Oncol 2005 Feb 01;23(4):800-7 PMID: 15681524 02/01/2005
  • Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. (Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM) J Clin Oncol 2004 Jun 01;22(11):2133-40 PMID: 15169799 06/01/2004
  • Hormones and radiation therapy in locally advanced adenocarcinoma of the prostate. (Lawton CA) Semin Radiat Oncol 2003 Apr;13(2):141-51 PMID: 12728443 05/03/2003
  • Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610. (Pollack A, Grignon DJ, Heydon KH, Hammond EH, Lawton CA, Mesic JB, Fu KK, Porter AT, Abrams RA, Shipley WU) J Clin Oncol 2003 Apr 01;21(7):1238-48 PMID: 12663710 03/29/2003
  • Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10. (Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M) Int J Radiat Oncol Biol Phys 2002 Dec 01;54(5):1302-10 PMID: 12459350 12/03/2002
  • Loss of renal function following bone marrow transplantation: an analysis of angiotensin converting enzyme D/I polymorphism and other clinical risk factors. (Juckett MB, Cohen EP, Keever-Taylor CA, Zheng Y, Lawton CA, Moulder JE, Klein J) Bone Marrow Transplant 2001 Feb;27(4):451-6 PMID: 11313676 04/21/2001
  • Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs. short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. (Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):947-56 PMID: 11240235 03/10/2001
  • Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. (Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE, Coughlin CT, Pilepich MV) Int J Radiat Oncol Biol Phys 2001 Mar 15;49(4):937-46 PMID: 11240234 03/10/2001
  • Prostatic carcinoma. (Lawton CA, Grignon D, Newhouse JH, Schellhammer PF, Kuban DA) Radiographics 1999 Jan-Feb;19(1):185-203 PMID: 9925399 01/30/1999
  • Long-term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. (Lawton CA, Cohen EP, Murray KJ, Derus SW, Casper JT, Drobyski WR, Horowitz MM, Moulder JE) Bone Marrow Transplant 1997 Dec;20(12):1069-74 PMID: 9466280 02/18/1998
  • Androgen suppression plus radiation versus radiation alone for patients with D1 (pN+) adenocarcinoma of the prostate (results based on a national prospective randomized trial, RTOG 85-31). Radiation Therapy Oncology Group. (Lawton CA, Winter K, Byhardt R, Sause WT, Hanks GE, Russell AH, Rotman M, Porter A, McGowan DG, DelRowe JD, Pilepich MV) Int J Radiat Oncol Biol Phys 1997 Jul 15;38(5):931-9 PMID: 9276357 07/15/1997
  • Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. (Pilepich MV, Caplan R, Byhardt RW, Lawton CA, Gallagher MJ, Mesic JB, Hanks GE, Coughlin CT, Porter A, Shipley WU, Grignon D) J Clin Oncol 1997 Mar;15(3):1013-21 PMID: 9060541 03/01/1997
  • p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. (Grignon DJ, Caplan R, Sarkar FH, Lawton CA, Hammond EH, Pilepich MV, Forman JD, Mesic J, Fu KK, Abrams RA, Pajak TF, Shipley WU, Cox JD) J Natl Cancer Inst 1997 Jan 15;89(2):158-65 PMID: 8998185 01/15/1997
  • Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer. (Byhardt RW, Vaickus L, Witt PL, Chang AY, McAuliffe T, Wilson JF, Lawton CA, Breitmeyer J, Alger ME, Borden EC) J Interferon Cytokine Res 1996 Nov;16(11):891-902 PMID: 8938564 11/01/1996
  • Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). (Lawton CA, Coleman CN, Buzydlowski JW, Forman JD, Marcial VA, DelRowe JD, Rotman M) Int J Radiat Oncol Biol Phys 1996 Oct 01;36(3):673-80 PMID: 8948352 10/01/1996
  • Pulmonary function changes in long-term survivors of bone marrow transplantation. (Gore EM, Lawton CA, Ash RC, Lipchik RJ) Int J Radiat Oncol Biol Phys 1996 Aug 01;36(1):67-75 PMID: 8823260 08/01/1996
  • Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomized comparative trial of the Radiation Therapy Oncology Group. (Pilepich MV, Krall JM, al-Sarraf M, John MJ, Doggett RL, Sause WT, Lawton CA, Abrams RA, Rotman M, Rubin P) Urology 1995 Apr;45(4):616-23 PMID: 7716842 04/01/1995
  • Bone marrow transplant nephropathy: radiation nephritis revisited. (Cohen EP, Lawton CA, Moulder JE) Nephron 1995;70(2):217-22 PMID: 7566307 01/01/1995
  • PSA screening. (Wilson JF, Hussey DH, Lawton CA, Leibel SA, Shipley WU) J Fam Pract 1994 Sep;39(3):216-7 PMID: 7521388 09/01/1994
  • Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms? (Lawton CA, Cantrell JE, Derus SW, Murray KJ, Byhardt RW, Wilson JF) Radiology 1994 Jul;192(1):37-40 PMID: 8208961 07/01/1994
  • Effect of nephrotoxic drugs on the development of radiation nephropathy after bone marrow transplantation. (Lawton CA, Fish BL, Moulder JE) Int J Radiat Oncol Biol Phys 1994 Mar 01;28(4):883-9 PMID: 8138441 03/01/1994
  • Clinical course of late-onset bone marrow transplant nephropathy. (Cohen EP, Lawton CA, Moulder JE, Becker CG, Ash RC) Nephron 1993;64(4):626-35 PMID: 8366991 01/01/1993
  • Is long-term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? (Lawton CA, Cox JD, Glisch C, Murray KJ, Byhardt RW, Wilson JF) Cancer 1992 Jun 01;69(11):2761-6 PMID: 1571906 06/01/1992
  • Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients. (Lawton CA, Barber-Derus SW, Murray KJ, Cohen EP, Ash RC, Moulder JE) Int J Radiat Oncol Biol Phys 1992;23(3):681-6 PMID: 1612975 01/01/1992
  • Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. (Weissman DE, Janjan NA, Erickson B, Wilson FJ, Greenberg M, Ritch PS, Anderson T, Hansen RM, Chitambar CR, Lawton CA) J Neurooncol 1991 Dec;11(3):235-9 PMID: 1726656 12/01/1991
  • Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. (Lundberg JH, Hansen RM, Chitambar CR, Lawton CA, Gottlieb M, Anderson T, Ash RC) J Clin Oncol 1991 Oct;9(10):1848-59 PMID: 1919635 10/01/1991
  • Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. (Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SR) Int J Radiat Oncol Biol Phys 1991 Sep;21(4):935-9 PMID: 1917622 09/01/1991
  • Late renal dysfunction in adult survivors of bone marrow transplantation. (Lawton CA, Cohen EP, Barber-Derus SW, Murray KJ, Ash RC, Casper JT, Moulder JE) Cancer 1991 Jun 01;67(11):2795-800 PMID: 2025844 06/01/1991
  • Technical modifications in hyperfractionated total body irradiation for T-lymphocyte deplete bone marrow transplant. (Lawton CA, Barber-Derus S, Murray KJ, Casper JT, Ash RC, Gillin MT, Wilson JF) Int J Radiat Oncol Biol Phys 1989 Aug;17(2):319-22 PMID: 2666364 08/01/1989
  • Extended-field radiation therapy for prostatic carcinoma with para-aortic lymph node metastasis. (Lawton CA, Glisch C, Byhardt RW, Sehring S, Hartz A, Cox JD) Am J Clin Oncol 1986 Aug;9(4):302-6 PMID: 3751968 08/01/1986
  • Last update: 11/02/2017
    jenkins-FCD Prod-153 3ca6710ea990189ceb85f4312e7298b5922ce1a6